Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
16.11.20
/
50%
€3.45
Target price
16.11.21
-
Performance (%)
-14.81%
End price
17.11.21
€2.94
Summary
This prediction ended on 17.11.21 with a price of €2.94. The price of Arbutus Biopharma Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.81%. Maxi_Scalibusa has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Arbutus Biopharma Corp. | 0.756% | 0.756% | 82.893% | 22.880% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% | 15.757% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% | 35.363% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% | 10.532% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% | 36.692% |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model